Agenus Inc. (AGEN) News
Filter AGEN News Items
AGEN News Results
|Loading, please wait...|
AGEN News Highlights
- AGEN's 30 day story count now stands at 15.
- Over the past 20 days, the trend for AGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about AGEN are AZN, III and MD.
Latest AGEN News From Around the Web
Below are the latest news stories about AGENUS INC that investors may wish to consider to help them evaluate AGEN as an investment opportunity.
Penny stocks are always a risky proposition.
In the latest trading session, Agenus (AGEN) closed at $2.31, marking a -1.28% move from the previous day.
Agenus (AGEN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
J&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination with balstilimab (PD-1), has demonstrated robust clinical activity in nine treatment-resistant tumor types, including microsatellite stable colorectal cancer LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to canc
Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; Todd Yancey, MD as Gl
Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.
GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.